Methylation analysis in urine fractions for optimal CIN3 and cervical cancer detection.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
Cervix Uteri
/ pathology
DNA Methylation
Early Detection of Cancer
/ methods
Female
Humans
Mass Screening
/ methods
Middle Aged
Papillomavirus Infections
/ diagnosis
Statistics, Nonparametric
Uterine Cervical Neoplasms
/ diagnosis
Uterine Cervical Dysplasia
/ diagnosis
Cervical cancer
Cervical intraepithelial neoplasia
Comparative analysis
DNA Methylation
Urine
Journal
Papillomavirus research (Amsterdam, Netherlands)
ISSN: 2405-8521
Titre abrégé: Papillomavirus Res
Pays: Netherlands
ID NLM: 101662552
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
15
11
2019
revised:
31
01
2020
accepted:
26
02
2020
pubmed:
17
3
2020
medline:
7
4
2021
entrez:
16
3
2020
Statut:
ppublish
Résumé
Urine sampling is an interesting solution for CIN3 and cervical cancer detection. Urine can be separated in different fractions: full void urine, urine sediment and urine supernatant. We aimed to determine which urine fraction is most competent for CIN3 and cervical cancer detection by methylation analysis. Urine samples (27 controls, 30 CIN3 and 17 cervical cancer) were processed into 3 fractions and tested for 5 methylation markers (ASCL1, GHSR, LHX8, SST, ZIC1). We determined Spearman correlation coefficients between fractions, compared methylation levels and calculated AUCs for CIN3 and cancer detection. In general strong correlations (r > 0.60) were found between urine fractions. Methylation levels increased significantly with severity of underlying disease in all urine fractions. CIN3 and controls differed significantly for 2 markers in full void urine, 4 markers in urine sediment and 1 marker in urine supernatant, with AUCs of 0.55-0.79. Comparison of cancer to controls was highly significant for all markers in all fractions, yielding AUCs of 0.87-0.99. Methylation analysis performs excellent in all urine fractions for cervical cancer detection. Our results indicate the potential of CIN3 detection by urinary methylation analysis, and demonstrate that urine sediment performs best to detect CIN3.
Identifiants
pubmed: 32171935
pii: S2405-8521(20)30022-7
doi: 10.1016/j.pvr.2020.100193
pmc: PMC7082622
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100193Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interests Rianne van den Helder, Nienke E. van Trommel, Annina P. van Splunter, Birgit I. Lissenberg-Witte and Maaike C.G. Bleeker have no interests to declare. Renske D.M. Steenbergen has a minority share in Self-screen B·V., a spin-off company of Amsterdam UMC, location VUmc. Self-screen B.V. holds patents related to the work (i.e., high-risk HPV test and methylation markers for cervical screening) and has developed and manufactured the methylation assay, which is licensed to Qiagen (QIAsure® Methylation Test).
Références
J Mol Diagn. 2004 May;6(2):101-7
pubmed: 15096565
BJOG. 2017 Aug;124(9):1356-1363
pubmed: 28391609
Clin Cancer Res. 2018 Jul 15;24(14):3456-3464
pubmed: 29632006
J Vis Exp. 2010 Nov 22;(45):
pubmed: 21189466
Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1053-1059
pubmed: 28223432
BMJ. 2010 Mar 11;340:c1040
pubmed: 20223872
J Clin Virol. 2016 Jan;74:26-31
pubmed: 26655264
Cancer Prev Res (Phila). 2016 Dec;9(12):915-924
pubmed: 27671338
Clin Cancer Res. 2017 Jul 15;23(14):3813-3822
pubmed: 28119363
Int J Biol Markers. 2005 Apr-Jun;20(2):134-6
pubmed: 16011045
Oncotarget. 2017 Aug 4;8(40):69162-69173
pubmed: 28978187
Eur J Cancer. 2015 Nov;51(16):2375-85
pubmed: 26296294
Eur J Obstet Gynecol Reprod Biol. 2017 Sep;216:1-11
pubmed: 28689156
Sci Rep. 2019 Feb 28;9(1):3088
pubmed: 30816167
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
CMAJ. 2000 Sep 5;163(5):513-8
pubmed: 11006761
BMJ. 2014 Oct 15;349:g6252
pubmed: 25319476
Int J Cancer. 2020 Mar 1;146(5):1230-1240
pubmed: 31107987
Eur J Clin Microbiol Infect Dis. 2012 May;31(5):627-40
pubmed: 21818524
PLoS One. 2018 Aug 24;13(8):e0200906
pubmed: 30142219
Eur J Clin Microbiol Infect Dis. 2014 Nov;33(11):2005-14
pubmed: 24916950
Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):773-82
pubmed: 25432954
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1178-84
pubmed: 17548682
BMJ. 2014 Sep 16;349:g5264
pubmed: 25232064